BIOPHARMA
By
Will Axsome Therapeutics’ FDA Priority Review of AXS-05 Address a Long-Standing Gap in Alzheimer’s Disease Agitation Treatment?
New York – December 31, 2025 — Axsome Therapeutics has reached a major regulatory milestone after the U.S.…
Can Dual Regulatory Approvals Position UltraGreen.ai as a Regional Leader in Fluorescence-Guided and AI-Enabled Surgery in Southeast Asia?
Singapore – December 31, 2025 — UltraGreen.ai Limited, a Singapore-based company specializing in fluorescence-guided surgery and digital health…
What Does SoftBank’s $41 Billion Bet on OpenAI Signal for the Future of Biopharma, Healthcare, and AI Infrastructure?
Global – December 2025 — SoftBank’s $41 billion investment in OpenAI represents one of the most consequential capital…
Did Ophthalmic Therapy Approvals in 2025 Redefine Vision Care—and Set the Stage for Accelerated Innovation in 2026?
Global – December 2025 — The ophthalmology therapeutic area entered a renewed phase of innovation in 2025, driven…
Can Merck Redefine Its Growth Story Beyond Keytruda as the Patent Clock Ticks?
Late January 2026 | Full-Year 2025 Earnings Preview | Oncology, Vaccines & Post-Keytruda Strategy Merck & Co. (known…
Can Novo Nordisk Defend Its Obesity Crown as Competition With Eli Lilly Intensifies in 2026?
Late January 2026 | Full-Year 2025 Earnings Preview | Obesity & Metabolic Disease Strategy Novo Nordisk is set…
